VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | An update on the PANGEA model

Annie Cowan, BA, Dana-Farber Cancer Institute, Boston, MA, gives an update on the results of the PANGEA model, which aims to better predict disease progression in patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma. This model has identified several dynamic biomarkers that can be used to predict disease progression including age, creatinin, and free light chain ratio, and it has been shown that this model outperforms currently used models to predict disease progression. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter